Q1 FY27 results analysis · July 31, 2026
Corona Remedies Ltd Q1 FY27 Results Analysis: PAT Surges 30%, Margin Expands 191 bps
+30.1%PAT year on year, Rs. 60.11 Cr
Quick summary
Corona Remedies Ltd reported Q1 FY27 numbers with revenue of Rs. 422.43 Cr (+21.90% YoY) and PAT growth of +30.10% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details
| Results date | July 31, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 422.43 Cr (+21.90% YoY) |
| PAT (Q1) | Rs. 60.11 Cr (+30.10% YoY) |
| EBITDA margin | 22.05% (+191 bps YoY) |
| EPS (Q1) | Rs. 9.83 (+30.20% YoY) |
| Market cap | Rs. 12,845.19 Cr |
| CMP | Rs. 2,098.80 |
Quarter Snapshot
CORONA delivered a strong Q1 with revenue growing 21.9% YoY, exceeding its 15% FY27 guidance. EBITDA margin expanded 191 bps to 22.05%, and PAT grew 30.1% YoY. The company gained market share, ranking 26th in IPM, and demonstrated operating leverage.
Key Investment Insights
Key Positives
- Revenue grew 21.9% YoY to Rs.422.43 Cr, above management's 15% FY27 revenue guidance.
- EBITDA grew 33.5% YoY to Rs.93.13 Cr, with margin expanding 191 bps YoY to 22.05%.
- PAT grew 30.1% YoY to Rs.60.11 Cr, above management's >20% PAT growth guidance.
- Market rank improved from 29th to 26th in IPM, fastest growing among top 30 companies.
Risk Factors
- Finance costs rose 35.2% YoY and 95% QoQ, though absolute level is low.
- Effective tax rate increased 140 bps YoY to 25.20%, reducing PAT.
- Depreciation grew 48.4% YoY due to capex cycle, pressuring net margins.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.